FATE THERAPEUTICS INC Proceeds from Issuance of Private Placement
FATE THERAPEUTICS INC (FATE) reported Proceeds from Issuance of Private Placement of $20.00 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2025-11-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2025-11-13
- FATE THERAPEUTICS INC proceeds from issuance of private placement for the quarter ending 2024-03-31 was $20.00M.
- FATE THERAPEUTICS INC proceeds from issuance of private placement for the quarter ending 2021-12-31 was $0.00.
- FATE THERAPEUTICS INC proceeds from issuance of private placement for the quarter ending 2020-12-31 was -$25.00K.
- FATE THERAPEUTICS INC proceeds from issuance of private placement for the quarter ending 2020-09-30 was $0.00.
- FATE THERAPEUTICS INC proceeds from issuance of private placement for fiscal 2022 was $0.00.
- FATE THERAPEUTICS INC proceeds from issuance of private placement for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- FATE THERAPEUTICS INC proceeds from issuance of private placement for fiscal 2020 was $49.98M.
| Period end | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|---|
| 2024-03-31 | $20.00M 10-Q · filed 2025-11-13 | |||
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | ||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-04 | |||
| 2020-12-31 | -$25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$25.00K derived: sum of 2 quarters · filed 2023-02-28 | $49.98M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $50.00M 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $50.00M 10-Q · filed 2021-08-04 | |||
| 2016-09-30 | $10.20M 10-Q · filed 2017-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |